Publications

Publications in 2022

  • Cummings JL, Devanand DP, Stahl SM. Dementia-related psychosis and the potential role for pimavanserin. Vol. 27, CNS Spectrums. Cambridge University Press; 2022. p. 7–15.
    https://pubmed.ncbi.nlm.nih.gov/32811586/

Publications in 2021

  • Abate G, Vezzoli M, Polito L, Guaita A, Albani D, Marizzoni M, et al. A conformation variant of p53 combined with machine learning identifies alzheimer disease in preclinical and prodromal stages. J Pers Med. 2021 Jan 1;11(1):1–16.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7823360/
  • Armstrong MJ, Sullivan JL, Amodeo K, Lunde A, Tsuang DW, Reger MA, et al. Suicide and Lewy body dementia: Report of a Lewy body dementia association working group. Vol. 36, International Journal of Geriatric Psychiatry. John Wiley and Sons Ltd; 2021. p. 373–82.
    https://pubmed.ncbi.nlm.nih.gov/33169435/
  • Caldwell JZK, Kinney JW, Ritter A, Salazar A, Wong CG, Cordes D, et al. Inflammatory cytokine levels implicated in Alzheimer’s disease moderate the effects of sex on verbal memory performance. Brain Behav Immun. 2021 Jul 1;95:27–35.
    https://pubmed.ncbi.nlm.nih.gov/33301871/
  • Cummings J. The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. Vol. 29, American Journal of Geriatric Psychiatry. Elsevier B.V.; 2021. p. 375–83.
    https://pubmed.ncbi.nlm.nih.gov/32819825/
  • Cummings J. Drug development for psychotropic, cognitive-enhancing, and disease-modifying treatments for alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2021 Jan 1;33(1):3
    https://pubmed.ncbi.nlm.nih.gov/33108950/
  • Cummings J. New approaches to symptomatic treatments for Alzheimer’s disease. Vol. 16, Molecular Neurodegeneration. BioMed Central Ltd; 2021.
    https://pubmed.ncbi.nlm.nih.gov/33441154/
  • Hellton KH, Cummings J, Vik-Mo AO, Nordrehaug JE, Aarsland D, Selbaek G, et al. The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. Multivariate Behav Res. 2021;56(1):70–85.
    https://pubmed.ncbi.nlm.nih.gov/32329370/
  • Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C, et al. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer’s dementia. Alzheimer’s Dement Transl Res Clin Interv. 2021;7(1).
    https://pubmed.ncbi.nlm.nih.gov/33614888/
  • Richardson S, Sinha A, Vahia I, Dawson W, Kaye J, Reynolds CF, et al. Brain Health Living Labs. Am J Geriatr Psychiatry. 2021 Jul 1;29(7):698–703.
    https://pubmed.ncbi.nlm.nih.gov/33342676/
  • Sabbagh MN, Pope E, Cordes L, Shi J, DeCourt B. Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD. Expert Opin Investig Drugs. 2021;30(1):39–44.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262379/
  • Salazar AM, Leisgang AM, Ortiz AA, Murtishaw AS, Kinney JW. Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer’s disease. Neurobiol Aging. 2021
    https://pubmed.ncbi.nlm.nih.gov/33232936/
  • Smith E, Ali D, Wilkerson B, Dawson WD, Sobowale K, Reynolds C, et al. A Brain Capital Grand Strategy: toward economic reimagination. Vol. 26, Molecular Psychiatry. Springer Nature; 2021. p. 3–22.
    https://pubmed.ncbi.nlm.nih.gov/33100330/

Publications in 2020

  • Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ, et al. The Future of Anti-Amyloid Trials. J Prev Alzheimer’s Dis. 2020 Mar 1;7(3):146–51.
    https://pubmed.ncbi.nlm.nih.gov/32463066/

  • Aisen PS, Sperling RA, Cummings J, Donohue MC, Langford O, Jimenez-Maggiora GA, et al. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):208–12.
    https://pubmed.ncbi.nlm.nih.gov/32920621/

  • Ballard C, Aarsland D, Cummings J, O’Brien J, Mills R, Molinuevo JL, et al. Drug repositioning and repurposing for Alzheimer disease. Vol. 16, Nature Reviews Neurology. Nature Research; 2020. p. 661–73.
    https://pubmed.ncbi.nlm.nih.gov/32939050/

  • Bauzon J, Lee G, Cummings J. Repurposed agents in the Alzheimer’s disease drug development pipeline. Alzheimer’s Res Ther. 2020 Aug 17;12(1).
    https://pubmed.ncbi.nlm.nih.gov/32807237/

  • Bayram E, Banks SJ, Shan G, Kaplan N, Caldwell JZK. Sex Differences in Cognitive Changes in de Novo Parkinson’s Disease. J Int Neuropsychol Soc. 2020 Feb 1;26(2):241–9.
    https://pubmed.ncbi.nlm.nih.gov/31822306/

  • Beach TG, Adler CH, Zhang N, Serrano GE, Sue LI, Driver-Dunckley E, et al. Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer’s disease dementia. PLoS One. 2020 Apr 1;15(4).
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176090/

  • Bennett LL, Stephen SJ, Bernick C, Shan G, Banks SJ. Sex Moderates the Relationship That Number of Professional Fights Has With Cognition and Brain Volumes. Front Neurol. 2020 Oct 29;11.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673387/

  • Bernick C, Shan G, Zetterberg H, Banks S, Mishra VR, Bekris L, et al. Longitudinal change in regional brain volumes with exposure to repetitive head impacts. Neurology. 2020 Jan 21;94(3):e232–40.
    https://pubmed.ncbi.nlm.nih.gov/31871218/

  • Cummings J. The Neuropsychiatric Inventory: Development and Applications. Vol. 33, Journal of Geriatric Psychiatry and Neurology. SAGE Publications Inc.; 2020. p. 73–84.
    https://pubmed.ncbi.nlm.nih.gov/32013737/

  • Cummings J. The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):288–90.
    https://pubmed.ncbi.nlm.nih.gov/32920632/

  • Cummings JL. Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach. Dement Geriatr Cogn Disord. 2020 Sep 1;49(1):22–37.
    https://pubmed.ncbi.nlm.nih.gov/32512572/

  • Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimer’s Dement Transl Res Clin Interv. 2020;6(1).
    https://pubmed.ncbi.nlm.nih.gov/32695874/

  • Cummings J, Pinto LC, Cruz M, Fischer CE, Gerritsen DL, Grossberg GT, et al. Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. Vol. 28, American Journal of Geriatric Psychiatry. Elsevier B.V.; 2020. p. 1256–69.
    https://pubmed.ncbi.nlm.nih.gov/32958332/

  • Dawson WD, Bobrow K, Ibanez A, Booi L, Pintado-Caipa M, Yamamoto S, et al. The necessity of diplomacy in brain health. Vol. 19, The Lancet Neurology. Lancet Publishing Group; 2020. p. 972–4.
    https://pubmed.ncbi.nlm.nih.gov/33212057/

  • Decourt B, Wilson J, Ritter A, Dardis C, Difilippo FP, Zhuang X, et al. MCLENA-1: A phase ii clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to alzheimer’s disease. Open Access J Clin Trials. 2020;12:1–13.
    https://pubmed.ncbi.nlm.nih.gov/32123490/

  • Digma LA, Madsen JR, Rissman RA, Jacobs DM, Brewer JB, Banks SJ. Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. Brain Commun. 2020;2(1).
    https://pubmed.ncbi.nlm.nih.gov/32337508/

  • Fang J, Pieper AA, Nussinov R, Lee G, Bekris L, Leverenz JB, et al. Harnessing endophenotypes and network medicine for Alzheimer’s drug repurposing. Vol. 40, Medicinal Research Reviews. John Wiley and Sons Inc; 2020. p. 2386–426.
    https://pubmed.ncbi.nlm.nih.gov/32656864/

  • Fischer CE, Ismail Z, Youakim JM, Creese B, Kumar S, Nuñez N, et al. Revisiting Criteria for Psychosis in Alzheimer’s Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. J Alzheimers Dis. 2020;73(3):1143–56.
    https://pubmed.ncbi.nlm.nih.gov/31884469/

  • Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R, et al. Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report. J Prev Alzheimer’s Dis. 2020 Mar 1;7(3):152–7.
    https://pubmed.ncbi.nlm.nih.gov/32420298/

  • Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. Am J Geriatr Psychiatry. 2020 Apr 1;28(4):383–400.
    https://pubmed.ncbi.nlm.nih.gov/31708380/

  • Hannestad J, Koborsi K, Klutzaritz V, Chao W, Ray R, Páez A, et al. Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer’s disease dementia. Alzheimer’s Dement Transl Res Clin Interv. 2020;6(1).
    https://pubmed.ncbi.nlm.nih.gov/33344754/

  • Henderson ST, Morimoto BH, Cummings JL, Farlow MR, Walker J. A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer’s Disease. J Alzheimer’s Dis. 2020 May 19;75(2):547–57.
    https://pubmed.ncbi.nlm.nih.gov/32310169/

  • Hjetland GJ, Nordhus IH, Pallesen S, Cummings J, Tractenberg RE, Thun E, et al. An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home. Front Psychiatry. 2020 Mar 13;11.
    https://pubmed.ncbi.nlm.nih.gov/32231600/

  • Jiang T, Cao B, Shan G. Accurate confidence intervals for risk difference in meta-analysis with rare events. BMC Med Res Methodol. 2020 Apr 30;20(1).
    https://pubmed.ncbi.nlm.nih.gov/32349702/

  • Jimenez-Maggiora GA, Bruschi S, Raman R, Langford O, Donohue M, Rafii MS, et al. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):226–33.
    https://pubmed.ncbi.nlm.nih.gov/32920624/

  • Langford O, Raman R, Sperling RA, Cummings J, Sun CK, Jimenez-Maggiora G, et al. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):213–8.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745538/

  • Sabbagh M, Sadowsky C, Tousi B, Agronin ME, Alva G, Armon C, et al. Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer’s disease. Alzheimer’s Dement. 2020 Apr 1;16(4):641–50.
    https://pubmed.ncbi.nlm.nih.gov/31879235/

  • Shan G, Bayram E, Caldwell JZK, Miller JB, Shen JJ, Gerstenberger S. Partial Correlation Coefficient for a Study With Repeated Measurements. Stat Biopharm Res. 2020 Jul 20;13(4):448–54.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8735669/

  • Shan G, Zhang H, Jiang T. Correlation Coefficients for a Study with Repeated Measures. Comput Math Methods Med. 2020;2020.
    https://pubmed.ncbi.nlm.nih.gov/32300374/

  • Stephen SJ, Shan G, Banks SJ, Bernick C, Bennett LL. The Relationship Between Fighting Style, Cognition, and Regional Brain Volume in Professional Combatants: A Preliminary Examination Using Brief Neurocognitive Measures. J Head Trauma Rehabil. 2020 May 1;35(3):E280–7.
    https://pubmed.ncbi.nlm.nih.gov/31834060/

  • Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain. Brain. 2020 Dec 1;143(12):3816–26.
    https://pubmed.ncbi.nlm.nih.gov/33253354/

  • Ternes K, Iyengar V, Lavretsky H, Dawson WD, Booi L, Ibanez A, et al. Brain health INnovation Diplomacy: A model binding diverse disciplines to manage the promise and perils of technological innovation. Vol. 32, International Psychogeriatrics. Cambridge University Press; 2020. p. 955–79.
    https://pubmed.ncbi.nlm.nih.gov/32019621/

  • Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer’s Dement. 2020 Nov 1;16(11):1553–60.
    https://pubmed.ncbi.nlm.nih.gov/31706733/

  • Walter S, Clanton TB, Langford OG, Rafii MS, Shaffer EJ, Grill JD, et al. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD). J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):219–25.
    https://pubmed.ncbi.nlm.nih.gov/32920623/

  • Walter S, Langford OG, Clanton TB, Jimenez-Maggiora GA, Raman R, Rafii MS, et al. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):234–41.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735207/

  • Wessels AM, Lines C, Stern RA, Kost J, Voss T, Mozley LH, et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer’s disease. Alzheimer’s Dement. 2020 Nov 1;16(11):1483–92.
    https://pubmed.ncbi.nlm.nih.gov/33049114/

  • Yang Z, Zhuang X, Sreenivasan K, Mishra V, Curran T, Cordes D. A robust deep neural network for denoising task-based fMRI data: An application to working memory and episodic memory. Med Image Anal. 2020 Feb 1;60.
    https://pubmed.ncbi.nlm.nih.gov/31811979/

Publications in 2019

  • Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN, et al. Unified staging system for Lewy body disorders: Clinicopathologic correlations and comparison to Braak staging. J Neuropathol Exp Neurol. 2019 Oct 1;78(10):891–9.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751070/
  • Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, et al. Enrichment factors for clinical trials in mild-to-moderate Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2019 Jan 1;5:164–74.
    https://pubmed.ncbi.nlm.nih.gov/31193334/
  • Banks SJ, Bayram E, Shan G, LaBelle DR, Bluett B. Non-motor predictors of freezing of gait in Parkinson’s disease. Gait Posture. 2019 Feb 1;68:311–6.
    https://pubmed.ncbi.nlm.nih.gov/30553992/
  • Banks SJ, Shifflett B, Berg JL, Sundermann E, Peavy G, Bondi MW, et al. Sex-specific composite scales for longitudinal studies of incipient Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2019 Jan 1;5:508–14.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804506/
  • Bayram E, Bluett B, Zhuang X, Cordes D, LaBelle DR, Banks SJ. Neural correlates of distinct cognitive phenotypes in early Parkinson’s disease. J Neurol Sci. 2019 Apr 15;399:22–9.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436969/
  • Bayram E, Kaplan N, Shan G, Caldwell JZK. The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson’s Disease. Aging, Neuropsychol Cogn. 2019 Aug 14;27(4):581–94.
    https://pubmed.ncbi.nlm.nih.gov/31411534/
  • Bayram E, Shan G, Cummings JL. Associations between comorbid TDP-43, Lewy body pathology, and neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimer’s Dis. 2019;69(4):953–61.
    https://pubmed.ncbi.nlm.nih.gov/31127776/
  • Bennett LL, Arias JJ, Ford PJ, Bernick C, Banks SJ. Concussion reporting and perceived knowledge of professional fighters. Phys Sportsmed. 2019 Jul 3;47(3):295–300.
    https://pubmed.ncbi.nlm.nih.gov/30479188/
  • Bernard K, Gouttefangeas S, Bretin S, Galtier S, Robert P, Holthoff-Detto V, et al. A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer’s disease and depressive symptoms. Alzheimer’s Dement Transl Res Clin Interv. 2019 Jan 1;5:231–40.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597919/
  • Brunet HE. P, Cummings JL. MS, Banks SJ. P, Miller JP. Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults. Aware Psychiatr Symptoms a Mix Clin Sample Older Adults. 2019 Aug 11;33(3).
    https://pubmed.ncbi.nlm.nih.gov/31401920/
  • Brunet HE, Caldwell JZK, Brandt J, Miller JB. Influence of sex differences in interpreting learning and memory within a clinical sample of older adults. Aging, Neuropsychol Cogn. 2019 Jan 20;27(1):18–39.
    https://pubmed.ncbi.nlm.nih.gov/30663493/
  • Brunet HE, Miller JB, Shi J, Chung B, Munter BT, Sabbagh MN. Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography? Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2019 Dec 1;11:424–9.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558087/
  • Caldwell JZK, Cummings JL, Banks SJ, Palmqvist S, Hansson O. Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume. Alzheimer’s Res Ther. 2019 Dec 26;11(1).
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933621/
  • Caldwell JZK, Zhuang X, Leavitt MJ, Banks SJ, Cummings J, Cordes D. Sex moderates amyloid and apolipoprotein ε4 effects on default mode network connectivity at rest. Front Neurol. 2019;10(AUG).
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710397/
  • Chiu MJ, Lue LF, Sabbagh MN, Chen TF, Chen HH, Yang SY. Long-Term Storage Effects on Stability of Aβ1-40, Aβ1-42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays. Dement Geriatr Cogn Dis Extra. 2019 Jan 1;9(1):77–86.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477481/
  • Cummings J. The National Institute on Aging—Alzheimer’s Association Framework on Alzheimer’s disease: Application to clinical trials. Vol. 15, Alzheimer’s and Dementia. Elsevier Inc.; 2019. p. 172–8.
    https://pubmed.ncbi.nlm.nih.gov/29936146/
  • Cummings JL, Tong G, Ballard C. Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. Vol. 67, Journal of Alzheimer’s Disease. IOS Press; 2019. p. 779–94.
    https://pubmed.ncbi.nlm.nih.gov/30689575/
  • Cummings J, Blennow K, Johnson K, Keeley M., Bateman RJ, Molinuevo JL, et al. Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force. J Prev Alzheimer’s Dis. 2019 Apr 18;6:157–63.
    https://pubmed.ncbi.nlm.nih.gov/31062825/
  • Cummings J, Feldman HH, Scheltens P. The “rights” of precision drug development for Alzheimer’s disease. Vol. 11, Alzheimer’s Research and Therapy. BioMed Central Ltd.; 2019.
    https://alzres.biomedcentral.com/articles/10.1186/s13195-019-0529-5
  • Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimer’s Dement Transl Res Clin Interv. 2019 Jan 1;5:272–93.
    https://pubmed.ncbi.nlm.nih.gov/31334330/
  • Cummings J, Passmore P, McGuinness B, Mok V, Chen C, Engelborghs S, et al. Souvenaid in the management of mild cognitive impairment: An expert consensus opinion. Vol. 11, Alzheimer’s Research and Therapy. BioMed Central Ltd.; 2019.
    https://pubmed.ncbi.nlm.nih.gov/31421681/
  • Cummings J, Ritter A, Rothenberg K. Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. Vol. 21, Current Psychiatry Reports. Current Medicine Group LLC 1; 2019.
    https://pubmed.ncbi.nlm.nih.gov/31392434/
  • Digma LA, Madsen JR, Reas ET, Dale AM, Brewer JB, Banks SJ. Tau and atrophy: Domain-specific relationships with cognition. Alzheimer’s Res Ther. 2019 Jul 27;11(1).
    https://pubmed.ncbi.nlm.nih.gov/31351484/
  • Dugger BN, Hoffman BR, Scroggins A, Serrano GE, Adler CH, Shill HA, et al. Tau immunoreactivity in peripheral tissues of human aging and select tauopathies. Neurosci Lett. 2019 Mar 23;696:132–9.
    https://pubmed.ncbi.nlm.nih.gov/30579993/
  • Durant J, Berg J-L, Banks SJ, Kaylegian J, Miller JB. Comparing the Boston Naming Test With the Neuropsychological Assessment Battery–Naming Subtest in a Neurodegenerative Disease Clinic Population. Assessment. 2019 Sep 13;28(5).
    https://pubmed.ncbi.nlm.nih.gov/31516023/
  • Durant J, Duff K, Miller JB. Regression-based formulas for predicting change in memory test scores in healthy older adults: Comparing use of raw versus standardized scores. J Clin Exp Neuropsychol. 2019 Feb 5;41(5):460–8.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099613/
  • Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease. N Engl J Med. 2019 Apr 11;380(15):1408–20.
    https://pubmed.ncbi.nlm.nih.gov/30970186/
  • Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, et al. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease. Alzheimer’s Res Ther. 2019 Aug 7;11(1).
    https://pubmed.ncbi.nlm.nih.gov/31387606/
  • El-Nazer R, Adler CH, Beach TG, Belden Christine M., Artz J, Shill HA, et al. Regional neuropathology distribution and verbal fluency impairments in Parkinson’s disease. Park Relat Disord. 2019 Aug;65:73–8.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774852/
  • Feng L, Li H, Oishi K, Mishra V, Song L, Peng Q, et al. Age-specific gray and white matter DTI atlas for human brain at 33, 36 and 39 postmenstrual weeks. Neuroimage. 2019 Jan 15;185:685–98.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289605/
  • Fitzhugh MC, Braden BB, Sabbagh MN, Rogalsky C, Baxter LC. Age-Related Atrophy and Compensatory Neural Networks in Reading Comprehension. J Int Neuropsychol Soc. 2019 Apr 29;25(6):569–82.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816336/
  • Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, et al. Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer’s Disease. J Alzheimer’s Dis. 2019 Jan 8;67(1):303–13.
    https://pubmed.ncbi.nlm.nih.gov/30636738/
  • Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, et al. Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimer’s Dis. 2019 Apr 18;6:164–8.
    https://pubmed.ncbi.nlm.nih.gov/31062826/
  • Goud KY, Moonla C, Mishra RK, Yu C, Narayan R, Litvan I, et al. Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management. ACS Sensors. 2019;4(8):2196–204.
    https://pubmed.ncbi.nlm.nih.gov/31403773/
  • Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B. Tau immunotherapies for Alzheimer’s disease. Expert Opin Investig Drugs. 2019 Jun 3;28(6):545–54.
    https://pubmed.ncbi.nlm.nih.gov/31094578/
  • Jalene S, Pharr J, Shan G, Poston B. Estimated Cardiorespiratory Fitness Is Associated With Reported Depression in College Students. Front Physiol. 2019 Sep 18;10.164. Jones SE, Idris A, Bullen JA, Miller
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6759774/
  • JB, Banks SJ. Relationship between cortical thickness and fluency in the memory disorders clinic population. Neuropsychologia. 2019 Jun 1;129:294–301.
    https://pubmed.ncbi.nlm.nih.gov/30951739/
  • Landers MR, Johnson KN, Johnson S, Ormsby T, Salgo DC, Zorn JB, et al. Pre-diagnosis physical activity habits are associated with age of diagnosis in Parkinson’s disease. Clin Park Relat Disord. 2019 Jan 1;1:25–30.
    https://pubmed.ncbi.nlm.nih.gov/34316595/
  • Landers MR, Navalta JW, Murtishaw AS, Kinney JW, Pirio Richardson S. A High-Intensity Exercise Boot Camp for Persons with Parkinson Disease: A Phase II, Pragmatic, Randomized Clinical Trial of Feasibility, Safety, Signal of Efficacy, and Disease Mechanisms. J Neurol Phys Ther. 2019 Jan 1;43(1):12–25.
    https://pubmed.ncbi.nlm.nih.gov/30531382/
  • Lee B, Bennett LL, Bernick C, Shan G, Banks SJ. The Relations among Depression, Cognition, and Brain Volume in Professional Boxers: A Preliminary Examination Using Brief Clinical Measures. J Head Trauma Rehabil. 2019 Nov 1;34(6):E29–39.
    https://pubmed.ncbi.nlm.nih.gov/31033751/
  • Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Vol. 28, Expert Opinion on Investigational Drugs. Taylor and Francis Ltd; 2019. p. 951–65.
    https://pubmed.ncbi.nlm.nih.gov/31614096/
  • Lue Yu-Min Kuo Marwan Sabbagh L-F, Lue L, Kuo Y, Sabbagh M. Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. Neurol Ther [Internet]. 2019;8:95–111. Available from: https://doi.org/10.6084/
    https://pubmed.ncbi.nlm.nih.gov/31833027/
  • Lue LF, Pai MC, Chen TF, Hu CJ, Huang LK, Lin WC, et al. Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects. Front Aging Neurosci. 2019 Sep 3;11.
    https://pubmed.ncbi.nlm.nih.gov/31551751/
  • Mark DK, John Z, Marwan QW, Sabbagh N. Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms. Neurol Ther [Internet]. 2019;8:79–94. Available from: https://doi.org/10.6084/
    https://pubmed.ncbi.nlm.nih.gov/30900186/
  • Mazurenko O, Shen J, Shan G, Greenway J. Nevada’s Medicaid Expansion and Admissions for Ambulatory Care-Sensitive Conditions. Am J Manag Care [Internet]. 2019 [cited 2022 Nov 3];24(5):157–63. Available from: https://hdl.handle.net/1805/21257
    https://pubmed.ncbi.nlm.nih.gov/29851447/
  • McCrudden MT, Marchand G, Schutz P. Mixed methods in educational psychology inquiry. Vol. 57, Contemporary Educational Psychology. Academic Press Inc.; 2019. p. 1–8.
    https://www.researchgate.net/publication/330319292_Mixed_methods_in_educational_psychology_inquiry
  • Mishra VR, Sreenivasan KR, Zhengshi Yang, Zhuang X, Cordes D, Mari Z, et al. Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology. 2019 Feb 25;94(8).
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136053/
  • Mishra VR, Sreenivasan KR, Zhuang X, Yang Z, Cordes D, Banks SJ, et al. Understanding white matter structural connectivity differences between cognitively impaired and nonimpaired active professional fighters. Hum Brain Mapp. 2019 Dec 1;40(17):5108–22.
    https://pubmed.ncbi.nlm.nih.gov/31403734/
  • Mishra VR, Sreenivasan KR, Zhuang X, Yang Z, Cordes D, Walsh RR. Influence of analytic techniques on comparing DTI-derived measurements in early stage Parkinson’s disease. Heliyon [Internet]. 2019; Available from: https://doi.org/10.1016/j.heliyon.2019.e01481https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458486/
  • Nance C, Ritter A, Miller JB, Lapin B, Banks SJ. The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer’s Disease. J Alzheimer’s Dis. 2019;70(4):982–93.
    https://pubmed.ncbi.nlm.nih.gov/31306127/
  • Ouyang M, Jeon T, Sotiras A, Peng Q, Mishra V, Halovanic C, et al. Differential cortical microstructural maturation in the preterm human brain with diffusion kurtosis and tensor imaging. Proc Natl Acad Sci U S A. 2019;116(10):4681–8.
    https://pubmed.ncbi.nlm.nih.gov/30782802/
  • Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, et al. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 Nov 1;217:72–83.
    https://pubmed.ncbi.nlm.nih.gov/31520897/
  • Sabbagh MN, Hendrix S, Harrison JE. FDA position statement “Early Alzheimer’s disease: Developing drugs for treatment, Guidance for Industry.” Vol. 5, Alzheimer’s and Dementia: Translational Research and Clinical Interventions. Elsevier Inc; 2019. p. 13–9.
    https://pubmed.ncbi.nlm.nih.gov/31650002/
  • Shan G, Hutson A, Wilding GE, Ma C, Tian G-L. Efficient statistical inference for a parallel study with missing data by using an exact method. J Biopharm Stat. 2019 Apr 29;29(3):478–90.
    https://pubmed.ncbi.nlm.nih.gov/31017028/
  • Shan G, Zhang H. Two-stage optimal designs with survival endpoint when the follow-up time is restricted. BMC Med Res Methodol. 2019 Apr 3;19(1).
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448233/
  • Shan G, Zhang H, Jiang T. Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping. Seq Anal. 2019 Jul 19;38(2):199–213.
    https://www.tandfonline.com/doi/abs/10.1080/07474946.2019.1611307?journalCode=lsqa20
  • Shen JJ, Shan G, Kim PC, Yoo JW, Dodge-Francis C, Lee YJ. Trends and Related Factors of Cannabis-Associated Emergency Department Visits in the United States: 2006-2014. J Addict Med. 2019 May 1;13(3):193–200.
    https://pubmed.ncbi.nlm.nih.gov/30418337/
  • Song M, Lieberman A, Fife T, Nielsen M, Hayden S, Sabbagh M, et al. A prospective study on gait dominant normal pressure hydrocephalus. Acta Neurol Scand. 2019 Apr 1;139(4):389–94.
    https://pubmed.ncbi.nlm.nih.gov/30676642/
  • Sorenson K, Sabbagh MN, Johnson M, Azuma T. Do Neuropsychological Profiles Differ between Amyloid PET Positive and Negative Amnestic MCI Subjects? J Alzheimers Dis Park. 2019 Aug 30;9(5).
    https://www.omicsonline.org/open-access/do-neuropsychological-profiles-differ-between-amyloid-pet-positive-and-negative-amnestic-mci-subjects-109449.html
  • Sreenivasan K, Mishra V, Bird C, Zhuang X, Yang Z, Cordes D, et al. Altered functional network topology correlates with clinical measures in very early-stage, drug-naïve Parkinson’s disease. Park Relat Disord. 2019 May 1;62:3–9.
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589361/
  • Yang Z, Zhuang X, Bird C, Sreenivasan K, Mishra V, Banks S, et al. Performing sparse regularization and dimension reduction simultaneously in multimodal data fusion. Front Neurosci. 2019;13(JUL).
    https://pubmed.ncbi.nlm.nih.gov/31333396/
  • Yang Z, Zhuang X, Sreenivasan K, Mishra V, Cordes D. Robust Motion Regression of Resting-State Data Using a Convolutional Neural Network Model. Front Neurosci [Internet]. 2019 Feb 28;13. Available from: https://www.frontiersin.org/article/10.3389/fnins.2019.00169/fullhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482337/
  • Zhang H, Song Y, Jiang B, Chen B, Shan G. Two-Stage Bagging Pruning for Reducing the Ensemble Size and Improving the Classification Performance. Math Probl Eng. 2019;2019.
    https://ouci.dntb.gov.ua/en/works/4zJogqa4/
  • Zhao T, Mishra V, Jeon T, Ouyang M, Peng Q, Chalak L, et al. Structural network maturation of the preterm human brain. Neuroimage. 2019 Jan 15;185:699–710.
    https://pubmed.ncbi.nlm.nih.gov/29913282/
  • Zhuang X, Yang Z, Sreenivasan KR, Mishra VR, Curran T, Nandy R, et al. Multivariate group-level analysis for task fMRI data with canonical correlation analysis. Neuroimage. 2019 Jul 1;194:25–41.
    https://pubmed.ncbi.nlm.nih.gov/30894332/

Publications in 2018

Publications in 2017

Publications in 2016

Publications in 2015